| Autor: |
Nigro, Olga, Oltolini, Chiara, Barzaghi, Federica, Uberti Foppa, Caterina, Cicalese, Maria Pia, Massimino, Maura, Schiavello, Elisabetta |
| Předmět: |
|
| Zdroj: |
Expert Review of Anticancer Therapy; 2023, Vol. 23 Issue 9, p927-942, 16p |
| Abstrakt: |
The severe acute respiratory syndrome coronavirus-2 pandemic significantly affected clinical practice, also in pediatric oncology units. Cancer patients needed to be treated with an adequate dose density despite the SARS-CoV-2 infection, balancing risks of developing severe COVID-19 disease. Although the pandemic spread worldwide, the prevalence of affected children was low. The percentage of children with severe illness was approximately 1–6%. Pediatric cancer patients represent a prototype of a previously healthy immune system that is hampered by the tumor itself and treatments, such as chemotherapy and steroids. Through a review of the literature, we reported the immunological basis of the response to SARS-CoV-2 infection, the existing antiviral treatments used in pediatric cancer patients, and the importance of vaccination. In conclusion, we reported the real-life experience of our pediatric oncology unit during the pandemic period. Starting from the data available in literature, and our experience, showing the rarity of severe COVID-19 disease in pediatric patients with solid tumors, we recommend carefully tailoring all the oncological treatments (chemotherapy/targeted therapy/stem cell transplantation/radiotherapy). The aim is the preservation of the treatment's timing, balanced with an evaluation of possible severe COVID-19 disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
